The Effects of Broccoli Sprout Extract on Obstructive Lung Disease

This study is currently recruiting participants.
Verified September 2012 by Johns Hopkins University
Information provided by (Responsible Party):
Robert Brown, Johns Hopkins University Identifier:
First received: October 13, 2009
Last updated: September 11, 2012
Last verified: September 2012

The purpose of this study is to examine whether broccoli sprout extract can effect lung function measurements in individuals with asthma and COPD.

Condition Intervention
Drug: broccoli sprout extract

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • The primary outcome is the change in bronchodilation and bronchoprotection after broccoli sprout extract [ Time Frame: end of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in biomarkers, Change in inflammatory mediators, Change in airway distensibility, Change in parenchyma [ Time Frame: end of study ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: October 2009
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: broccoli sprout extract Drug: broccoli sprout extract
consumption of broccoli sprout extract for 2 weeks


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • asthma
  • COPD

Exclusion Criteria:

  • currently on chronic oral steroid medications
  • current respiratory symptoms
  • pregnant
  • FEV1 less than 40% predicted at baseline
  • extreme degrees of bronchial hyperreactivity
  • recent respiratory infection (<3 weeks)
  • unstable symptoms in the prior month
  • a history of intubation for respiratory symptoms within the past year
  • any history of cardiac disease.
  Contacts and Locations
Please refer to this study by its identifier: NCT00994604

Contact: Curt Reynolds 410-299-2429

United States, Maryland
Johns Hopkins Medical Institutions Recruiting
Baltimore, Maryland, United States, 21205
Contact: Curt Reynolds    410-299-2429      
Principal Investigator: Robert H Brown, M.D., M.P.H.         
Sponsors and Collaborators
Johns Hopkins University
  More Information

No publications provided

Responsible Party: Robert Brown, Professor, Johns Hopkins University Identifier: NCT00994604     History of Changes
Other Study ID Numbers: RB-001
Study First Received: October 13, 2009
Last Updated: September 11, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lung Diseases, Obstructive
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on April 17, 2014